Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health (JAGX) stock is on the rise Thursday after announcing a meeting concerning an upcoming SPAC merger in Italy. The post JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting appeared first on InvestorPlace.

JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting

The stock price of Jaguar Health Inc (NASDAQ: JAGX) has increased by over 15% pre-market today. This is why it happened.

JAGX Stock Price Increases Over 15% Pre-Market: Why It Happened

Ideanomics Inc

Marathon Digital Holdings

If the first week of 2021 is the sign of things to come this year, traders and investors are going to make a lot of money. 4 NASDAQ stocks that really lit up the first week of 2021 were Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: […]

4 Hot NASDAQ Stocks: Ideanomics (NASDAQ: IDEX), Jaguar Health (NASDAQ: JAGX), Marathon Patent Group (NASDAQ: MARA), and Riot Blockchain (NASDAQ: RIOT)

SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. To access the audio recording and slides from the webcast, click here.

Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the total number to over 1.5 million doses. Regeneron discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

Why Regeneron, Jaguar Health And Seneca Are Moving Today

This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher

SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870 shares of common stock at a purchase price of $3.38 per share for gross proceeds of approximately $15.0 million in a registered direct offering priced above-the-market under Nasdaq rules. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering.

Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules

If you believe in the future of plant-based medical treatments, then a long position in JAGX stock could offer exposure to this technology. The post Don't Try to Tame Jaguar Health Stock As It Rips Higher appeared first on InvestorPlace.

Don't Try to Tame Jaguar Health Stock As It Rips Higher

REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference

New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.

Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler' COVID-19 Recovery Patients in Europe

The developer of plant-based medicines has a promising drug pipeline.

Why Jaguar Health Stock Skyrocketed 49% Today

JAGX stock is on the move today as Jaguar Health continues to gain attention. Here's what you should know about the biopharma play now.

JAGX Stock: 11 Things to Know as Jaguar Health Rockets Higher

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased over 20% shortly after the market opened this morning. This is why it happened.

JAGX Stock Price Increased Over 20%: Why It Happened

Lechlemer development focused on possible tropical disease priority review voucher SAN FRANCISCO, CA / ACCESSWIRE / January 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals ("Napo"), Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera. As previously announced, Napo is receiving preclinical services from the National Institute of Allergy and Infectious Diseases ("NIAID") to support lechlemer development.

Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from

Shares of Jaguar Health Inc., a developer of plant-based medicines for people and animals, soared more than 40% on Tuesday in heavy volume, extending their recent strong gains and putting the stock on track for its highest level since mid-2019.

Jaguar Health shares soar 40% in heavy volume, on track for 18-month high

JAGX shares are once again on the move this week. Here's what you should know about the maker of the antidiarrheal treatment Mytesi.

JAGX Stock: 12 Things to Know About Fast-Moving Jaguar Health

JAGX stock is up on news that Jaguar Health just signed a royalty deal that will allow the company to pursue new FDA approvals. The post JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today appeared first on InvestorPlace.

JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today

BIOLASE

Senseonics Holdings

Tonix Pharmaceuticals Hld

This article is going to explain what penny stocks are and discuss four penny stocks under $1 to watch as small-cap stocks continue a hot streak this winter. First thing's first, what are penny stocks?

4 Hot Penny Stocks Trading Under $1 That Need To Be On Your Watchlist

No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer (Mytesi®) for cancer therapy-related diarrhea (CTD), for which patient enrollment is progressing SAN FRANCISCO, CA / ACCESSWIRE / December 23, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the "Royalty Purchase Price") a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the "Royalty Repayment Amount"), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full. Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline, including funding continued patient enrollment for the pivotal Phase 3 trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy ("cancer therapy‑related diarrhea" (CTD)), which the Company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), initiated this past October.

Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream

All proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern regarding appearance of new coronavirus strain underscoring urgency to seek European conditional approval for crofelemer for ‘long-hauler' syndrome gastrointestinal distress as strategy pursued in potential merger of Napo EU with the European Post Pandemic Recovery Equity special purpose acquisition company (SPAC) SAN FRANCISCO, CA / ACCESSWIRE / December 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results of Jaguar's December 9, 2020 Special Meeting of Stockholders (the "Special Meeting"), which, as previously announced, was adjourned until December 22, 2020. Two proposals were submitted to and approved by the stockholders of the Company at the Special Meeting.

Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar

The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) is trading at more than 50% today. This is why it happened.

JAGX Stock Price Increases Over 50%: Why It Happened

Jaguar Health (JAGX) is on the move Tuesday as shares of JAGX stock continue to rise and InvestorPlace has what investors need to know. The post Jaguar Health: 10 Things for JAGX Stock Investors to Know About the Pharmaceutical Company appeared first on InvestorPlace.

Jaguar Health: 10 Things for JAGX Stock Investors to Know About the Pharmaceutical Company

OncoCyte

Jaguar Health (NASDAQ: JAGX) shares are trading higher on Monday after the company announced its plans to develop and commercialize its Crofelemer. Jaguar Health is a commercial-stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products.

Why Jaguar Health And OncoCyte Are Trading Higher Today

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q3 2020 Results - Earnings Call Transcript 

The following post is sponsored by Jaguar Health, Inc. It is for informational purposes only and not intended to be investing advice. With more than 30 years of ethnobotanical field research and ethnopharmacological compound analysis encompassing plant species and medical traditions from indigenous communities throughout the world's rainforest and tropical biomes, the management team at Jaguar Health (NASDAQ: JAGX) has garnered a unique reservoir of knowledge and expertise within the biotech industry.

News for Jaguar Health Stock (JAGX)